RANTES and MCP-3 Inhibit the Replication of T-cell-tropic Human Immunodeficiency Virus Type 1 Strains (SF-2, MN, and HE)

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1997 Oct 6

PMID 9311806

Citations 9

Authors

D Schols

P Proost

J Van Damme

E De Clercq

Affiliations

Soon will be listed here.

Abstract

The effects of the C-C chemokines RANTES (regulation upon activation normal T-cell expressed and secreted) and MCP-3 (monocyte chemotactic protein 3) on human immunodeficiency virus (HIV) replication in normal human peripheral blood mononuclear cells (PBMC) activated in vitro with phytohemagglutinin (PHA) were investigated. The following T-cell line-tropic (T-tropic) HIV strains were tested: HIV type 1 (HIV-1) SF-2, HIV-1 IIIB, HIV-1 MN, HIV-1 NDK, HIV-1 HE, HIV-1 NL4-3, HIV-2 ROD, and HIV-2 EHO. The strain most sensitive to the antiviral effects of RANTES and MCP-3 appeared to be HIV-1 SF-2. A 50% inhibitory concentration for HIV-1 SF-2 of 4 ng of RANTES per ml was obtained, and that of MCP-3 was about 1 ng/ml. However, MCP-3 was inactive at 100 ng/ml. Other HIV-1 strains, such as MN and HE, were less sensitive to the antiviral effects of RANTES and MCP-3, whereas all the other HIV strains tested were insensitive. Although the ratio of CD3+ CD4+ to CD3+ CD8+ T cells was the same in HIV-infected PBMC cultures treated or untreated with the chemokines, RANTES and MCP-3 interfered with the binding of monoclonal antibody (MAb) OKT4 to the CD4 receptor on T cells but not with the binding of MAb OKT4A. Therefore, RANTES and MCP-3 not only interfere with the HIV-induced fusion process but also have some modulating effect on the CD4 cell receptor. The chemokines did not affect HIV-1 binding to PHA-stimulated PBMC. Taken together, our observations point to the important role that both RANTES and MCP-3 may play in inhibiting HIV-1 replication of certain T-tropic strains in primary PBMC cultures. This may have important implications for immunotherapeutic strategies designed to slow down disease progression in AIDS.

Citing Articles

Recent Advances in the Discovery and Function of Antimicrobial Molecules in Platelets.

Aquino-Dominguez A, Romero-Tlalolini M, Torres-Aguilar H, Aguilar-Ruiz S Int J Mol Sci. 2021; 22(19).

PMID: 34638568 PMC: 8508203. DOI: 10.3390/ijms221910230.

Cytokine and Chemokine Profiling in Patients with Hand, Foot and Mouth Disease in Singapore and Malaysia.

Teo F, Nyo M, Wong A, Tan N, Koh M, Chan Y Sci Rep. 2018; 8(1):4087.

PMID: 29511232 PMC: 5840398. DOI: 10.1038/s41598-018-22379-6.

Vgamma9Vdelta2 T cell-mediated non-cytolytic antiviral mechanisms and their potential for cell-based therapy.

Poccia F, Agrati C, Martini F, Mejia G, Wallace M, Malkovsky M Immunol Lett. 2005; 100(1):14-20.

PMID: 16115692 PMC: 7172763. DOI: 10.1016/j.imlet.2005.06.025.

Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.

Marozsan A, Torre V, Johnson M, Ball S, Cross J, Templeton D J Virol. 2001; 75(18):8624-38.

PMID: 11507208 PMC: 115108. DOI: 10.1128/jvi.75.18.8624-8638.2001.

Applications of flow cytometry to clinical microbiology.

Alvarez-Barrientos A, Arroyo J, Canton R, Nombela C, Sanchez-Perez M Clin Microbiol Rev. 2001; 13(2):167-95.

PMID: 10755996 PMC: 100149. DOI: 10.1128/CMR.13.2.167.

References

Mann D, Arthur L, Robey W, Wernet P, Schneider E, Blattner W . HLA-DR is involved in the HIV-1 binding site on cells expressing MHC class II antigens. J Immunol. 1988; 141(4):1131-6. View

Spire B, Sire J, Zachar V, Rey F, Barre-Sinoussi F, Galibert F . Nucleotide sequence of HIV1-NDK: a highly cytopathic strain of the human immunodeficiency virus. Gene. 1989; 81(2):275-84. DOI: 10.1016/0378-1119(89)90188-1. View

Dean M, Carrington M, Winkler C, Huttley G, Smith M, Allikmets R . Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort,.... Science. 1996; 273(5283):1856-62. DOI: 10.1126/science.273.5283.1856. View

Levy J, Hoffman A, Kramer S, Landis J, Shimabukuro J, Oshiro L . Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science. 1984; 225(4664):840-2. DOI: 10.1126/science.6206563. View

Cheng-Mayer C, Shioda T, Levy J . Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120. J Virol. 1991; 65(12):6931-41. PMC: 250799. DOI: 10.1128/JVI.65.12.6931-6941.1991. View

Paxton W, Martin S, Tse D, OBrien T, Skurnick J, VanDevanter N . Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med. 1996; 2(4):412-7. DOI: 10.1038/nm0496-412. View

Mackay C . Chemokine receptors and T cell chemotaxis. J Exp Med. 1996; 184(3):799-802. PMC: 2192795. DOI: 10.1084/jem.184.3.799. View

Clayton L, Sieh M, PIOUS D, Reinherz E . Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding. Nature. 1989; 339(6225):548-51. DOI: 10.1038/339548a0. View

Dragic T, Litwin V, Allaway G, Martin S, Huang Y, Nagashima K . HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996; 381(6584):667-73. DOI: 10.1038/381667a0. View

10.

Kowalski M, Potz J, Basiripour L, Dorfman T, Goh W, Terwilliger E . Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science. 1987; 237(4820):1351-5. DOI: 10.1126/science.3629244. View

11.

Samson M, Libert F, Doranz B, Rucker J, Liesnard C, Farber C . Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996; 382(6593):722-5. DOI: 10.1038/382722a0. View

12.

Proost P, Van Leuven P, Wuyts A, Ebberink R, Opdenakker G, Van Damme J . Chemical synthesis, purification and folding of the human monocyte chemotactic proteins MCP-2 and MCP-3 into biologically active chemokines. Cytokine. 1995; 7(2):97-104. DOI: 10.1006/cyto.1995.1013. View

13.

Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier J, Schwartz O . The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 1996; 382(6594):833-5. DOI: 10.1038/382833a0. View

14.

Pauwels R, Andries K, Desmyter J, Schols D, Kukla M, Breslin H . Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature. 1990; 343(6257):470-4. DOI: 10.1038/343470a0. View

15.

Van Damme J, Proost P, Lenaerts J, Opdenakker G . Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J Exp Med. 1992; 176(1):59-65. PMC: 2119277. DOI: 10.1084/jem.176.1.59. View

16.

Gallo R, Salahuddin S, Popovic M, Shearer G, Kaplan M, Haynes B . Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984; 224(4648):500-3. DOI: 10.1126/science.6200936. View

17.

Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath P . The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996; 85(7):1135-48. DOI: 10.1016/s0092-8674(00)81313-6. View

18.

Taub D, Proost P, Murphy W, Anver M, Longo D, Van Damme J . Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest. 1995; 95(3):1370-6. PMC: 441477. DOI: 10.1172/JCI117788. View

19.

Schall T, Bacon K, Toy K, Goeddel D . Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature. 1990; 347(6294):669-71. DOI: 10.1038/347669a0. View

20.

Sozzani S, Sallusto F, Luini W, Zhou D, Piemonti L, Allavena P . Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J Immunol. 1995; 155(7):3292-5. View